Tanya Dougherty, PharmD, BCPS

home / authors / tanya-dougherty-pharmd-bcps

Articles

December 14th 2020

Type 2 Diabetes in the US Managed Care Setting: The Burden of Disease and Rationale for an Oral Glucagon-like Peptide-1 Receptor Agonist

Tanya Dougherty, PharmD, BCPS Michael Heile, MD, FAAFP

December 13th 2020

Efficacy of Oral Semaglutide: Overview of the PIONEER Clinical Trial Program and Implications for Managed Care

Helena W. Rodbard, MD, FACP, MACE Tanya Dougherty, PharmD, BCPS Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP

December 12th 2020

Cardiovascular Outcomes, Safety, and Tolerability With Oral Semaglutide: Insights for Managed Care

Ildiko Lingvay, MD, MPH, MSCS Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP Tanya Dougherty, PharmD, BCPS

December 11th 2020

The Importance of Patient-Reported Outcomes in Type 2 Diabetes: Insight From the PIONEER Program With Oral Semaglutide

Doron Schneider, MD Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP Tanya Dougherty, PharmD, BCPS

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: November 1st 2024 | Updated: November 21st 2024

Table Multiple Myeloma Trials November 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions